L M Dunkle
Overview
Explore the profile of L M Dunkle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaul S, Kline M, Church J, Dunkle L
Antimicrob Agents Chemother
. 2001 Feb;
45(3):758-63.
PMID: 11181356
The results of the development of dosing guidelines for stavudine in human immunodeficiency virus (HIV)-infected children are summarized. Included in the integrated analyses were 21 and 33 HIV-infected pediatric and...
2.
Elion R, Kaul S, Knupp C, Adler M, Cross A, Dunkle L, et al.
Clin Ther
. 2000 Jul;
21(11):1853-63.
PMID: 10890257
We assessed the safety profile, tolerability, and antiviral effect of 12 weeks of triple combination therapy with stavudine (d4T), didanosine (ddI), and nelfinavir in patients who had not previously received...
3.
Pollard R, Peterson D, Hardy D, Pottage J, Murphy R, Gathe J, et al.
J Acquir Immune Defic Syndr
. 1999 Oct;
22(1):39-48.
PMID: 10534145
The safety and antiretroviral effects of didanosine and stavudine in combination were evaluated in 86 people infected with HIV with CD4 counts between 200 and 500 cells/mm3 who had received...
4.
Haworth S, Christofalo B, Anderson R, Dunkle L
J Acquir Immune Defic Syndr Hum Retrovirol
. 1998 Mar;
17(3):235-8.
PMID: 9495223
Penetration of stavudine into the cerebrospinal fluid (CSF) was studied in healthy humans. In this open, randomized study, a single oral dose of 40 mg of stavudine was given to...
5.
Kline M, Fletcher C, Federici M, Harris A, Evans K, Rutkiewicz V, et al.
Pediatrics
. 1996 Jun;
97(6 Pt 1):886-90.
PMID: 8657531
Objectives: To obtain preliminary information on the pharmacokinetic properties, tolerance, safety, and antiviral activity of combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus (HIV) infection....
6.
Kline M, Dunkle L, Church J, Goldsmith J, Harris A, Federici M, et al.
Pediatrics
. 1995 Aug;
96(2 Pt 1):247-52.
PMID: 7630678
Objectives: To determine the pharmacokinetic properties, tolerance, safety, and preliminary activity of stavudine in human immunodeficiency virus (HIV)-infected children. Design: Phase I/II, open and dose-ranging (0.125 to 4 mg/kg/day in...
7.
Dunkle L
N Engl J Med
. 1995 Jun;
332(24):1647; author reply 1647-8.
PMID: 7753147
No abstract available.
8.
Petersen E, Hardy W, Schwartz R, Sacks H, Follansbee S, Peterson D, et al.
J Infect Dis
. 1995 Mar;
171 Suppl 2:S131-9.
PMID: 7861018
In a multicenter, randomized, open-label, dose-ranging study to determine the relative effects of three dose levels of stavudine on CD4 lymphocyte count, weight gain, and hematologic variables in patients infected...
9.
Murray H, Squires K, Weiss W, Sledz S, Sacks H, Hassett J, et al.
J Infect Dis
. 1995 Mar;
171 Suppl 2:S123-30.
PMID: 7861017
In a phase I trial of stavudine in AIDS or AIDS-related complex (ARC), antiviral effects and safety were assessed in 41 patients treated with dosages of 0.5-12.0 mg/kg/day. Among evaluable...
10.
Anderson R, Dunkle L, Smaldone L, Adler M, Wirtz C, Kriesel D, et al.
J Infect Dis
. 1995 Mar;
171 Suppl 2:S118-22.
PMID: 7861016
In a randomized, double-blind, large, simple trial, the safety and efficacy of two weight-adjusted dose levels of stavudine were evaluated in patients with advanced human immunodeficiency virus (HIV) infection. All...